Initial combination therapy for rapid and effective control of moderate and severe hypertension

Area of Science:

• Cardiology
• Public Health
• Pharmacology

Background:

• Moderate (grade 2) and severe (grade 3) hypertension pose significant public health challenges, linked to elevated cardiovascular risk.
• Effective blood pressure (BP) control is often challenging in advanced stages of hypertension, increasing the risk of hypertensive emergencies.
• Current treatment guidelines are not met by less than 50% of patients with moderate or severe hypertension in the U.S.

Purpose of the Study:

• To review the cardiovascular risks associated with moderate and severe hypertension.
• To examine physician inertia as a barrier to effective blood pressure management.
• To advocate for increased use of initial combination therapy for improved BP control.

Main Methods:

• Literature review focusing on cardiovascular risk in moderate and severe hypertension.
• Analysis of physician inertia and its impact on treatment adherence.
• Evaluation of the efficacy and safety of initial combination therapy versus monotherapy.

Main Results:

• Physician inertia contributes to suboptimal BP control in a significant patient population.
• Initial combination therapy, specifically with a renin-angiotensin system (RAS) inhibitor and diuretic, demonstrates rapid and effective BP reduction.
• This combination therapy shows a comparable adverse event profile to monotherapy.

Conclusions:

• Increased utilization of initial combination therapy can surmount barriers to effective BP management.
• RAS inhibitor and diuretic combination therapy is a promising strategy for achieving BP goals in moderate to severe hypertension.
• Early and effective treatment, including combination therapy, is crucial for preventing hypertensive complications and reducing cardiovascular risk.